Education
About Us
Working with TipRanks
Follow Us
CombiGene AB (SE:COMBI)
:COMBI
COMBI Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.27 - kr4.12
Previous CloseN/A
Volume11.77K
Average Volume (3M)15.52K
Market Cap
kr50.10M
Enterprise ValueN/A
Total Cash (Recent Filing)kr73.75M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
May 08, 2025EPS EstimateN/A
Last Dividend Ex-Date
Sep 29, 2016Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding19,801,197
10 Day Avg. Volume8,157
30 Day Avg. Volume15,523
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
COMBI FAQ
What was CombiGene AB’s price range in the past 12 months?
CombiGene AB lowest stock price was kr1.27 and its highest was kr4.12 in the past 12 months.
What is CombiGene AB’s market cap?
CombiGene AB’s market cap is kr50.10M.
When is CombiGene AB’s upcoming earnings report date?
CombiGene AB’s upcoming earnings report date is May 08, 2025 which is in 12 days.
How were CombiGene AB’s earnings last quarter?
CombiGene AB released its earnings results on Feb 14, 2025. The company reported -kr0.715 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.715.
Is CombiGene AB overvalued?
According to Wall Street analysts CombiGene AB’s price is currently Overvalued.
Does CombiGene AB pay dividends?
CombiGene AB pays a Notavailable dividend of kr1.169 which represents an annual dividend yield of N/A. See more information on CombiGene AB dividends here
What is CombiGene AB’s EPS estimate?
CombiGene AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CombiGene AB have?
CombiGene AB has 19,801,197 shares outstanding.
What happened to CombiGene AB’s price movement after its last earnings report?
CombiGene AB reported an EPS of -kr0.715 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.345%.
Which hedge fund is a major shareholder of CombiGene AB?
Currently, no hedge funds are holding shares in SE:COMBI
---
Company Description
CombiGene AB
CombiGene AB (COMBI) is a biotechnology company focused on the development of innovative gene therapy solutions to treat severe life-altering diseases. Operating within the healthcare sector, CombiGene specializes in leveraging cutting-edge genetic technologies to create therapies that address unmet medical needs. The company's core products are centered around gene therapy treatments, particularly in the areas of neurological disorders and metabolic diseases.
---
Technical Analysis
ExpreS2ion Biotech Holding AB
―
Modus Therapeutics Holding AB
―
OncoZenge AB
―
Spago Nanomedical AB
―
Sprint Bioscience AB
―
---